Miltefosine enhances infectivity of a miltefosine-resistant Leishmania infantum strain by attenuating its innate immune recognition.
<h4>Background</h4>Miltefosine (MIL) is currently the only oral drug available to treat visceral leishmaniasis but its use as first-line monotherapy has been compromised by an increasing treatment failure. Despite the scarce number of resistant clinical isolates, MIL-resistance by mutati...
Saved in:
Main Authors: | Dimitri Bulté, Lieselotte Van Bockstal, Laura Dirkx, Magali Van den Kerkhof, Carl De Trez, Jean-Pierre Timmermans, Sarah Hendrickx, Louis Maes, Guy Caljon |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/45bfdf7d1c8b4744b809bf929f0a57eb |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers
by: Yu G, et al.
Published: (2021) -
Alginate nanoparticles as non-toxic delivery system for miltefosine in the treatment of candidiasis and cryptococcosis
by: Spadari CC, et al.
Published: (2019) -
Lipid raft‐disrupting miltefosine preferentially induces the death of colorectal cancer stem‐like cells
by: So‐Yeon Park, et al.
Published: (2021) -
A Novel Bioimpedance-Based Detection of Miltefosine Susceptibility Among Clinical Leishmania donovani Isolates of the Indian Subcontinent Exhibiting Resistance to Multiple Drugs
by: Souradeepa Ghosh, et al.
Published: (2021) -
Relapse after Treatment with Miltefosine for Visceral Leishmaniasis Is Associated with Increased Infectivity of the Infecting <named-content content-type="genus-species">Leishmania donovani</named-content> Strain
by: Keshav Rai, et al.
Published: (2013)